Moss, 9 February 2024
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the fourth quarter and full year 2023.
Highlights
- Sales of MNOK 37.5 in 4Q23, up 34% vs 4Q22 (23% organic growth). Full year sales of MNOK 135.2 in 2023, up 33% vs 2022 (21% organic growth)
- EBITDA of NOK -1.0 million in 4Q23 versus NOK -1.5 million in 4Q22. Irregularities related to raw materials resulted in an increased COGS estimated to NOK 1.8 million in 4Q23. EBITDA for the full year 2023 of NOK 3.3 million, compared to NOK -13.0 million in 2022
- Year-end cash position at NOK 87.6 million, up NOK 6.0 million compared to year-end 2022
- Cystatin C sales increased 49% in 4Q23 compared to 4Q22 and 41% in 2023 vs 2022
- Third party sales increased 96% in 4Q23 compared to 4Q22 and 67% in 2023 vs 2022
- Optimisation of the NT-proBNP prototype continues with noteworthy progress in 4Q23 and preparations for production scalability experiments were initiated
GDASA Interim report 4Q 2023
GDASA Q4 23 presentation
Webcast
Gentian’s CEO Hilja Ibert and CFO Njaal Kind will present the results today at 09.00 am, followed by a Q&A session. Join the webcast and submit questions via the following link:
https://attendee.gotowebinar.com/register/2787750596465033558
The webcast will be available on the company website after the presentation.
IR contact:
Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Njaal Kind, CFO at Gentian Diagnostics ASA, on 9 February 2024 at 08:00 CET.
About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.